Kadri Altundag - Academia.edu (original) (raw)

Papers by Kadri Altundag

Research paper thumbnail of Possible Association Between Nanobacteria and Malignant Microcalcifications In Breast Cancer

Research paper thumbnail of Tobacco Smoking and Breast Cancer

Research paper thumbnail of Increased mean corpuscular volume of erythrocytes predicts the response to metronomic cyclophosphamide, capecitabine and bevacizumab treatment: Is it true for capecitabine treatment or more?

Research paper thumbnail of Lactation, Galactorrhea, and Timing of Reduction Mammaplasty

Plastic and Reconstructive Surgery, 2006

ABSTRACT An abstract is unavailable. This article is available as HTML full text and PDF.

Research paper thumbnail of Effect of concomitant use of pentoxifylline and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer

Medical Oncology, 2006

We evaluated the effects of pentoxifylline (PTX) and alpha-tocopherol on the clinical outcome of ... more We evaluated the effects of pentoxifylline (PTX) and alpha-tocopherol on the clinical outcome of 66 patients with stage IIIB non-small cell lung cancer in a randomized clinical trial. All patients received 46 Gy of external radiotherapy to the primary tumor and regional lymph, nodes with an additional 14-Gy dose to the primary tumor. Thirty-three of the 66 patients also received

Research paper thumbnail of Anal Tumor Diagnosed After the Recovery of Fournier Gangrene

Digestive Diseases and Sciences, 2006

Dig Dis Sci (2006) 51:889–890 DOI 10.1007/s10620-006-9098-0 ... Anal Tumor Diagnosed After the Re... more Dig Dis Sci (2006) 51:889–890 DOI 10.1007/s10620-006-9098-0 ... Anal Tumor Diagnosed After the Recovery of Fournier Gangrene ... Yesim Elgin · Taciser Demirkasimoglu · Bulent Kucukplakci · Muzaffer B. Altundag · Kadri Altundag · Cem Misirlioglu · Ergun Sanri · Handan Erkal · Isil ...

Research paper thumbnail of Angiotensin 1–7 and risk for breast cancer recurrence

We read with great interest the article by Rodgers et al. [3]. In their phase I/II dose escalatio... more We read with great interest the article by Rodgers et al. [3]. In their phase I/II dose escalation study, they tried to determine the safety and efficacy of Angiotensin 1–7 in patients with breast cancer. Their data showed that Angiotensin 1–7 might be beneficial in attenuating ...

Research paper thumbnail of Safety of Tamoxifen During Pregnancy: 3 Case Reports and Review of the Literature

Research paper thumbnail of Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer

Research paper thumbnail of Characteristics of breast cancer patients with central nervous system metastases: a single-center experience

Journal of the National Medical Association, 2008

The aim of this study was to assess the characteristics of breast cancer patients with central ne... more The aim of this study was to assess the characteristics of breast cancer patients with central nervous system (CNS) metastases and factors associated with survival after development of CNS metastasis. One-hundred-forty-four patients with brain metastases were retrospectively analyzed. Median age at the time of brain metastasis diagnosis was 48.9. Median time between initial diagnosis and development of brain metastasis was 36 months. Fourteen cases had leptomeningeal involvement. Twenty-two patients (15.3%) had single metastasis. Ten percent of the patients had surgery, 94% had radiotherapy and 63% had chemotherapy. Median survival after development of brain metastasis was 7.4 months. Survival of patients with single metastasis was significantly longer than those with multiple metastases (33.5 vs. 6.5 months, p = 0.0006). Survival of patients who received chemotherapy was significantly longer than those who received radiotherapy alone (9.9 vs. 2 months, p < 0.0001). In multivaria...

Research paper thumbnail of Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer

Research paper thumbnail of Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain

Onkologie, 2012

The aim of this study was to determine the efficacy and safety of loading-dose intravenous (i.v.)... more The aim of this study was to determine the efficacy and safety of loading-dose intravenous (i.v.) ibandronate in women with breast cancer and bone metastases. In this prospective, phase II, open-label study, 13 women with breast cancer, bone metastases, and moderate/severe bone pain received ibandronate 6 mg/day (i.v. loading-dose 15 min infusion over 3 consecutive days) with follow-up until day 14. Endpoints included pain response (primary), duration until pain response, analgesic use, Karnofsky index, safety (including hematologic, biochemical, and urine examinations), and adverse events. Pain intensity decreased on days 7 and 14 versus day 1 (mean visual analogue scale score: 3.2 ± 2.2 and 3.0 ± 2.1 versus 6.1 ± 0.9, respectively; p &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.01 for both). Mean time to pain response was 8.2 ± 3.3 days. Mean rate of analgesic use decreased (69.2%, 16.7% and 15.4% on days 1, 7 and 14, respectively). Mean Karnofsky index score increased (80.8 ± 13.1 and 80.8 ± 13.2, on days 7 and 14 versus 77.7 ± 11.7 on day 1; p &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.05 on both days). Bone pain and analgesic use decreased in women with breast cancer and bone metastases following loading dose i.v. ibandronate which was well-tolerated with no renal safety concerns.

Research paper thumbnail of Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis

Cancer, Jan 15, 2007

Breast cancer is the second most common cause of central nervous system (CNS) metastases. Several... more Breast cancer is the second most common cause of central nervous system (CNS) metastases. Several risk factors for CNS metastases have been reported. The objective of the current study was to describe clinicopathologic characteristics and prognostic factors in breast cancer patients with CNS metastases. The authors retrospectively evaluated clinical data from 420 patients who had been diagnosed with breast cancer and CNS metastasis between 1994 and 2004 at the University of Texas M. D. Anderson Cancer Center. The median age of the patients at the time of diagnosis of breast cancer was 45 years (range, 25-77 years). Premenopausal and postmenopausal patients were distributed equally. Most patients had invasive ductal histology (91.2%), grade 3 tumors (81.4%) (using the modified Black nuclear grading system), T2 tumor classification (40.1%), and N1 lymph node status (59.7%) diagnosis. Forty percent of patients had estrogen receptor (ER)-positive disease, and 34% had progesterone recept...

Research paper thumbnail of Monoclonal antibody-based targeted therapy in breast cancer

Current medicinal chemistry. Anti-cancer agents, 2005

Advances in molecular biology have identified tumor markers that not only predict prognosis and t... more Advances in molecular biology have identified tumor markers that not only predict prognosis and therapeutic response but may also function as potential therapeutic targets. Activated growth factor receptors induce breast cancer cells to proliferate, invade, and metastasize in experimental models. Overexpression of growth factor receptors has been associated with a poor clinical outcome in breast cancer patients. Biological therapy with monoclonal antibody directed against growth factor receptor pathways became important targeted therapy in breast cancer and is being pursued on various fronts. The anti-HER2 antibody trastuzumab is approved in the metastatic setting and is now trying to find the place in the adjuvant setting. Phase II and III studies with antibodies directed against VEGF and EGFR are also ongoing.

Research paper thumbnail of Human papilloma virus and breast cancer

Research paper thumbnail of Hormone receptor status as a prognostic factor affecting the outcome of brain metastases

Supportive Care in Cancer, 2007

Research paper thumbnail of Bisphosphonates may also be effective in the management of non-skeletal metastases in hormone receptor positive breast cancer

Research paper thumbnail of US and CT findings of multicentric leiomyosarcomatosis

European Radiology, 1999

This article presents a case of leiomyosarcomatosis with widespread lesions involving the soft ti... more This article presents a case of leiomyosarcomatosis with widespread lesions involving the soft tissues and the most unlikely organs such as thyroid and salivary glands, pancreas, ligamentum teres, bladder wall, and bones without lymph node or distant metastasis. The CT and US findings of this rare phenomenon are discussed with regard to the literature.

Research paper thumbnail of Impact of Acetylsalicylic Acid on the Clinicopathological Characteristics and Prognosis of Patients with Invasive Breast Cancer

Breast Care, 2014

The impact of acetylsalicylic acid (ASA) on the clinicopathological characteristics of breast can... more The impact of acetylsalicylic acid (ASA) on the clinicopathological characteristics of breast cancer has not yet been elucidated in detail; we therefore aimed to investigate the effects of ASA on the clinicopathological characteristics of patients with breast cancer. Patients diagnosed with breast cancer were retrospectively analyzed. Breast cancer patients who were taking ASA at the time of breast cancer diagnosis were enrolled as ASA users (n = 84); matching patients with the same age who were not taking ASA were included as control group (n = 890). The median age was 56 (range 34-82) years in both groups. ASA users had a significantly lower incidence of grade II-III tumors compared to non-users (P = 0.02). The other clinicopathological characteristics and treatment histories were similar in both groups. In patients using ASA, the disease-free survival (DFS) rate was 97.3%, 89.4%, and 79.9% and in non-users it was 94.1%, 81.8%, and 70.9% in the 1rst, 3rd, and 5th year, respectively (P = 0.01). In aspirin users, the overall survival rate was 95.0%, 90.6%, and 87.6% and in non-users it was 98.1%, 91.2%, and 85.5% in the 1rst, 3rd, and 5th year, respectively (P = 0.50). Using ASA at the time of breast cancer diagnosis was associated with significantly improved DFS in breast cancer patients.

Research paper thumbnail of Cetuximab-induced esophageal ulcer: the first report in literature

Libyan Journal of Medicine, 2014

Research paper thumbnail of Possible Association Between Nanobacteria and Malignant Microcalcifications In Breast Cancer

Research paper thumbnail of Tobacco Smoking and Breast Cancer

Research paper thumbnail of Increased mean corpuscular volume of erythrocytes predicts the response to metronomic cyclophosphamide, capecitabine and bevacizumab treatment: Is it true for capecitabine treatment or more?

Research paper thumbnail of Lactation, Galactorrhea, and Timing of Reduction Mammaplasty

Plastic and Reconstructive Surgery, 2006

ABSTRACT An abstract is unavailable. This article is available as HTML full text and PDF.

Research paper thumbnail of Effect of concomitant use of pentoxifylline and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer

Medical Oncology, 2006

We evaluated the effects of pentoxifylline (PTX) and alpha-tocopherol on the clinical outcome of ... more We evaluated the effects of pentoxifylline (PTX) and alpha-tocopherol on the clinical outcome of 66 patients with stage IIIB non-small cell lung cancer in a randomized clinical trial. All patients received 46 Gy of external radiotherapy to the primary tumor and regional lymph, nodes with an additional 14-Gy dose to the primary tumor. Thirty-three of the 66 patients also received

Research paper thumbnail of Anal Tumor Diagnosed After the Recovery of Fournier Gangrene

Digestive Diseases and Sciences, 2006

Dig Dis Sci (2006) 51:889–890 DOI 10.1007/s10620-006-9098-0 ... Anal Tumor Diagnosed After the Re... more Dig Dis Sci (2006) 51:889–890 DOI 10.1007/s10620-006-9098-0 ... Anal Tumor Diagnosed After the Recovery of Fournier Gangrene ... Yesim Elgin · Taciser Demirkasimoglu · Bulent Kucukplakci · Muzaffer B. Altundag · Kadri Altundag · Cem Misirlioglu · Ergun Sanri · Handan Erkal · Isil ...

Research paper thumbnail of Angiotensin 1–7 and risk for breast cancer recurrence

We read with great interest the article by Rodgers et al. [3]. In their phase I/II dose escalatio... more We read with great interest the article by Rodgers et al. [3]. In their phase I/II dose escalation study, they tried to determine the safety and efficacy of Angiotensin 1–7 in patients with breast cancer. Their data showed that Angiotensin 1–7 might be beneficial in attenuating ...

Research paper thumbnail of Safety of Tamoxifen During Pregnancy: 3 Case Reports and Review of the Literature

Research paper thumbnail of Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer

Research paper thumbnail of Characteristics of breast cancer patients with central nervous system metastases: a single-center experience

Journal of the National Medical Association, 2008

The aim of this study was to assess the characteristics of breast cancer patients with central ne... more The aim of this study was to assess the characteristics of breast cancer patients with central nervous system (CNS) metastases and factors associated with survival after development of CNS metastasis. One-hundred-forty-four patients with brain metastases were retrospectively analyzed. Median age at the time of brain metastasis diagnosis was 48.9. Median time between initial diagnosis and development of brain metastasis was 36 months. Fourteen cases had leptomeningeal involvement. Twenty-two patients (15.3%) had single metastasis. Ten percent of the patients had surgery, 94% had radiotherapy and 63% had chemotherapy. Median survival after development of brain metastasis was 7.4 months. Survival of patients with single metastasis was significantly longer than those with multiple metastases (33.5 vs. 6.5 months, p = 0.0006). Survival of patients who received chemotherapy was significantly longer than those who received radiotherapy alone (9.9 vs. 2 months, p < 0.0001). In multivaria...

Research paper thumbnail of Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer

Research paper thumbnail of Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain

Onkologie, 2012

The aim of this study was to determine the efficacy and safety of loading-dose intravenous (i.v.)... more The aim of this study was to determine the efficacy and safety of loading-dose intravenous (i.v.) ibandronate in women with breast cancer and bone metastases. In this prospective, phase II, open-label study, 13 women with breast cancer, bone metastases, and moderate/severe bone pain received ibandronate 6 mg/day (i.v. loading-dose 15 min infusion over 3 consecutive days) with follow-up until day 14. Endpoints included pain response (primary), duration until pain response, analgesic use, Karnofsky index, safety (including hematologic, biochemical, and urine examinations), and adverse events. Pain intensity decreased on days 7 and 14 versus day 1 (mean visual analogue scale score: 3.2 ± 2.2 and 3.0 ± 2.1 versus 6.1 ± 0.9, respectively; p &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.01 for both). Mean time to pain response was 8.2 ± 3.3 days. Mean rate of analgesic use decreased (69.2%, 16.7% and 15.4% on days 1, 7 and 14, respectively). Mean Karnofsky index score increased (80.8 ± 13.1 and 80.8 ± 13.2, on days 7 and 14 versus 77.7 ± 11.7 on day 1; p &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.05 on both days). Bone pain and analgesic use decreased in women with breast cancer and bone metastases following loading dose i.v. ibandronate which was well-tolerated with no renal safety concerns.

Research paper thumbnail of Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis

Cancer, Jan 15, 2007

Breast cancer is the second most common cause of central nervous system (CNS) metastases. Several... more Breast cancer is the second most common cause of central nervous system (CNS) metastases. Several risk factors for CNS metastases have been reported. The objective of the current study was to describe clinicopathologic characteristics and prognostic factors in breast cancer patients with CNS metastases. The authors retrospectively evaluated clinical data from 420 patients who had been diagnosed with breast cancer and CNS metastasis between 1994 and 2004 at the University of Texas M. D. Anderson Cancer Center. The median age of the patients at the time of diagnosis of breast cancer was 45 years (range, 25-77 years). Premenopausal and postmenopausal patients were distributed equally. Most patients had invasive ductal histology (91.2%), grade 3 tumors (81.4%) (using the modified Black nuclear grading system), T2 tumor classification (40.1%), and N1 lymph node status (59.7%) diagnosis. Forty percent of patients had estrogen receptor (ER)-positive disease, and 34% had progesterone recept...

Research paper thumbnail of Monoclonal antibody-based targeted therapy in breast cancer

Current medicinal chemistry. Anti-cancer agents, 2005

Advances in molecular biology have identified tumor markers that not only predict prognosis and t... more Advances in molecular biology have identified tumor markers that not only predict prognosis and therapeutic response but may also function as potential therapeutic targets. Activated growth factor receptors induce breast cancer cells to proliferate, invade, and metastasize in experimental models. Overexpression of growth factor receptors has been associated with a poor clinical outcome in breast cancer patients. Biological therapy with monoclonal antibody directed against growth factor receptor pathways became important targeted therapy in breast cancer and is being pursued on various fronts. The anti-HER2 antibody trastuzumab is approved in the metastatic setting and is now trying to find the place in the adjuvant setting. Phase II and III studies with antibodies directed against VEGF and EGFR are also ongoing.

Research paper thumbnail of Human papilloma virus and breast cancer

Research paper thumbnail of Hormone receptor status as a prognostic factor affecting the outcome of brain metastases

Supportive Care in Cancer, 2007

Research paper thumbnail of Bisphosphonates may also be effective in the management of non-skeletal metastases in hormone receptor positive breast cancer

Research paper thumbnail of US and CT findings of multicentric leiomyosarcomatosis

European Radiology, 1999

This article presents a case of leiomyosarcomatosis with widespread lesions involving the soft ti... more This article presents a case of leiomyosarcomatosis with widespread lesions involving the soft tissues and the most unlikely organs such as thyroid and salivary glands, pancreas, ligamentum teres, bladder wall, and bones without lymph node or distant metastasis. The CT and US findings of this rare phenomenon are discussed with regard to the literature.

Research paper thumbnail of Impact of Acetylsalicylic Acid on the Clinicopathological Characteristics and Prognosis of Patients with Invasive Breast Cancer

Breast Care, 2014

The impact of acetylsalicylic acid (ASA) on the clinicopathological characteristics of breast can... more The impact of acetylsalicylic acid (ASA) on the clinicopathological characteristics of breast cancer has not yet been elucidated in detail; we therefore aimed to investigate the effects of ASA on the clinicopathological characteristics of patients with breast cancer. Patients diagnosed with breast cancer were retrospectively analyzed. Breast cancer patients who were taking ASA at the time of breast cancer diagnosis were enrolled as ASA users (n = 84); matching patients with the same age who were not taking ASA were included as control group (n = 890). The median age was 56 (range 34-82) years in both groups. ASA users had a significantly lower incidence of grade II-III tumors compared to non-users (P = 0.02). The other clinicopathological characteristics and treatment histories were similar in both groups. In patients using ASA, the disease-free survival (DFS) rate was 97.3%, 89.4%, and 79.9% and in non-users it was 94.1%, 81.8%, and 70.9% in the 1rst, 3rd, and 5th year, respectively (P = 0.01). In aspirin users, the overall survival rate was 95.0%, 90.6%, and 87.6% and in non-users it was 98.1%, 91.2%, and 85.5% in the 1rst, 3rd, and 5th year, respectively (P = 0.50). Using ASA at the time of breast cancer diagnosis was associated with significantly improved DFS in breast cancer patients.

Research paper thumbnail of Cetuximab-induced esophageal ulcer: the first report in literature

Libyan Journal of Medicine, 2014